Literature DB >> 12833127

Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord.

L Shi1, G P Tang, S J Gao, Y X Ma, B H Liu, Y Li, J M Zeng, Y K Ng, K W Leong, S Wang.   

Abstract

Gene delivery into the spinal cord provides a potential approach to the treatment of spinal cord traumatic injury, amyotrophic lateral sclerosis, and spinal muscular atrophy. These disorders progress over long periods of time, necessitating a stable expression of functional genes at therapeutic levels for months or years. We investigated in this study the feasibility of achieving prolonged transgene expression in the rat spinal cord through repeated intrathecal administration of plasmid DNA complexed with 25 kDa polyethylenimine (PEI) into the lumbar subarachnoid space. With a single injection, DNA/PEI complexes could provide transgene expression in the spinal cord 40-fold higher than naked plasmid DNA. The transgene expression at the initial level persisted for about 5 days, with a low-level expression being detectable for at least 8 weeks. When repeated dosing was tested, a 70% attenuation of gene expression was observed following reinjection at a 2-week interval. This attenuation was associated with apoptotic cell death and detected even using complexes containing a noncoding DNA that did not mediate any gene expression. When each component of the complexes, PEI polymer or naked DNA alone, were tested in the first dosing, no reduction was found. Using polyethylene glycol (PEG)-grafted PEI for DNA complexes, no attenuation of gene expression was detected after repeated intrathecal injections, even in those rats receiving three doses, administered 2 weeks apart. Lumbar puncture is a routine and relatively nontraumatic clinical procedure. Repeated administration of DNA complexed with PEG-grafted PEI through this less invasive route may prolong the time span of transgene expression when needed, providing a viable strategy for the gene therapy of spinal cord disorders.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833127     DOI: 10.1038/sj.gt.3301970

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  22 in total

Review 1.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 2.  Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.

Authors:  Ryan G Soderquist; Melissa J Mahoney
Journal:  Expert Opin Drug Deliv       Date:  2010-03       Impact factor: 6.648

3.  Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound.

Authors:  Emmanuel Thévenot; Jessica F Jordão; Meaghan A O'Reilly; Kelly Markham; Ying-Qi Weng; Kevin D Foust; Brian K Kaspar; Kullervo Hynynen; Isabelle Aubert
Journal:  Hum Gene Ther       Date:  2012-10-15       Impact factor: 5.695

Review 4.  Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

Authors:  Mikhail I Papisov; Vasily V Belov; Kimberley S Gannon
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

Review 5.  Polyethylene glycol-conjugated copolymers for plasmid DNA delivery.

Authors:  Minhyung Lee; Sung Wan Kim
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

Review 6.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

Review 7.  Non-viral gene therapy for spinal cord regeneration.

Authors:  Li Yao; Sheng Yao; William Daly; William Hendry; Anthony Windebank; Abhay Pandit
Journal:  Drug Discov Today       Date:  2012-05-24       Impact factor: 7.851

8.  Immunogenicity of intrathecal plasmid gene delivery: cytokine release and effects on transgene expression.

Authors:  Travis S Hughes; Stephen J Langer; Salla I Virtanen; Raymond A Chavez; Linda R Watkins; Erin D Milligan; Leslie A Leinwand
Journal:  J Gene Med       Date:  2009-09       Impact factor: 4.565

9.  Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain.

Authors:  Erin D Milligan; Ryan G Soderquist; Stephanie M Malone; John H Mahoney; Travis S Hughes; Stephen J Langer; Evan M Sloane; Steven F Maier; Leslie A Leinwand; Linda R Watkins; Melissa J Mahoney
Journal:  Neuron Glia Biol       Date:  2006-11

10.  Polyethylenimine-mediated gene delivery to the lung and therapeutic applications.

Authors:  Sante Di Gioia; Massimo Conese
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.